## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.6% below STRENGTH zone (4.0-10.0%); PEG 1.73 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Thrivent Financial for Lutherans Has $4.97 Million Position in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251220T111615 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans reduced its stake in Henry Schein, Inc. by 42.1% in Q2, bringing its position to 68,043 shares valued at approximately $4.97 million. Despite this, other major institutions like Ameriprise Financial and Norges Bank significantly increased their holdings, leading to institutional ownership of 96.62%. Henry Schein recently beat EPS estimates and provided positive FY2025 guidance, with analysts currently holding a "Hold" consensus rating and a target price of $76.92.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.73 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.4B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.73 |
| Forward P/E | 14.7 |
| Current P/E | 15.8 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.2% to 2.6% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.4pp (needs >4.0% for momentum thesis). MRS_5 (-0.8%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.2% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.59% (CS: 70) | Neutral |
| RSI_14 | 67.6 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.101x | Above |
| vs SMA200 | 1.118x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.58
- **Stop Loss:** $74.64 (3.8% risk)
- **Target:** $80.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 408
- **Position Value:** $31,652.64
- **Portfolio %:** 31.65%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*